{
    "nctId": "NCT05731258",
    "briefTitle": "Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen",
    "officialTitle": "Clinical Observational Study of Postoperative Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Liposomal Doxorubicin, Efficacy, Safety, Postoperative Adjuvant Treatment",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "Cardiac safety",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female, aged 18-75 years;\n2. Primary breast cancer diagnosed histopathologically;\n3. Adjuvant chemotherapy regimens include liposomal doxorubicin;\n4. ECoG PS score: 0-1 points;\n5. Left ventricular ejection fraction (LVEF) \u2265 55%;\n6. Estimated survival \u2265 6 months;\n7. Major organ function is normal, i.e. meets the following criteria:\n\n   \u2460 And white blood cells \u2265 4.0 \u00d7 10 9 / L, neutrophil count (ANC) \u2265 1.5 \u00d7 10 9 /L\uff1b\u2461 Platelets \u2265 100 \u00d7 10 9 /L\uff1b\u2462 And hemoglobin \u2265 10 g / dl; \u2463 Serum creatinine \u2264 1.5 \u00d7 \u2464 the upper limit of normal (ULN) Mmol / L and aspartate transaminase (AST) \u2264 2.5\n\n   \u00d7 ULN\uff1b\u2465 Alanine transaminase (ALT) \u2264 2.5 \u00d7 ULN\uff1b\u2466 Total bilirubin \u2264 1.5 \u00d7 ULN\uff1b\u2467 Serum creatinine \u2264 1.5 \u00d7 ULN\uff1b\n8. Subjects voluntarily join this study, sign the informed consent form, have good compliance and cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Pregnant, lactating patients;\n2. Breast cancer has been found to have distant metastasis;\n3. Those with peripheral nervous system disorders caused by the disease or with a history of significant mental disorders and central nervous system disorders;\n4. Those with severe infection or active peptic ulcer requiring treatment;\n5. Allergic to chemotherapy drugs;\n6. Cancer free period less than 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in situ of the cervix;\n7. Severe liver disease (e.g., cirrhosis, etc.), renal disease, respiratory disease, or uncontrolled diabetes;\n8. Patients who are participating in other clinical trials or within a month.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}